argenx SE (NASDAQ:ARGX) Shares Acquired by Royal Bank of Canada

Royal Bank of Canada raised its holdings in shares of argenx SE (NASDAQ:ARGX) by 6.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,953 shares of the company’s stock after buying an additional 2,341 shares during the period. Royal Bank of Canada owned about 0.06% of argenx worth $23,340,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. GeoWealth Management LLC lifted its position in argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock valued at $31,000 after buying an additional 18 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its position in argenx by 5.6% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock valued at $234,000 after buying an additional 20 shares in the last quarter. SG Americas Securities LLC lifted its position in argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after buying an additional 21 shares in the last quarter. Farther Finance Advisors LLC lifted its position in argenx by 38.2% during the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after buying an additional 21 shares in the last quarter. Finally, Dynasty Wealth Management LLC lifted its position in argenx by 3.4% during the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock valued at $416,000 after buying an additional 22 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ARGX has been the topic of a number of analyst reports. Wells Fargo & Company lifted their price objective on shares of argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. HC Wainwright reiterated a “buy” rating and set a $720.00 price objective on shares of argenx in a research note on Tuesday, April 8th. Sanford C. Bernstein upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a research note on Monday, March 17th. William Blair restated an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Finally, Wedbush restated an “outperform” rating and issued a $715.00 price target on shares of argenx in a research note on Friday, April 11th. One analyst has rated the stock with a hold rating, twenty have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $698.11.

argenx Price Performance

ARGX stock opened at $587.61 on Friday. argenx SE has a 1-year low of $359.37 and a 1-year high of $678.21. The firm has a fifty day moving average price of $589.78 and a two-hundred day moving average price of $612.99. The firm has a market cap of $35.88 billion, a price-to-earnings ratio of -667.74 and a beta of 0.57.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.26. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $748.34 million. As a group, analysts expect that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.